Fresh analysis suggests that people who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese people often shed substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments should be aware of the risk of fast weight regain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight in about one and a half years.
Weighing Therapies
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
The team point out that people who shed pounds through lifestyle changes alone usually experience a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Quick Regain
Nutrition scientists suggest the mechanism of the injections is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication means appetite is unsuppressed, making binge eating much more probable."
A Chronic Condition?
The NHS advise the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the high risk of relapse, the therapy is often long-term.
This view is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
People who have come off the medication describe a intense return of appetite.
"I experienced a trigger flipping and you're instantly extremely hungry," recalled an individual.
This challenge is exacerbated if users have not established sustainable dietary or behavioural changes during therapy.
Widespread Adoption
Figures suggest that millions of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are potent tools for weight loss, they are not a standalone fix and lasting health benefits likely depends on integrated lifestyle support.
